Cited by 1,683Angiogenesis and VEGF in CancerCancer Cells and MetastasisMathematical Biology Tumor Growth

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Boehm, Thomas, Folkman, Judah, Browder, Timothy, O'Reilly, Michael S.·1997·Nature

Open this paper in CoChat — free account

Abstract

Acquired drug resistance is a major problem in the treatment of cancer. Of the more than 500,000 annual deaths from cancer in the United States, many follow the development of resistance to chemotherapy. The emergence of resistance depends in part on the genetic instability, heterogeneity and high mutational rate of tumour cells. In contrast, endothelial cells are genetically stable, homogeneous and have a low mutational rate. Therefore, antiangiogenic therapy directed against a tumour's endothelial cells should, in principle, induce little or no drug resistance. Endostatin, a potent angiogenesis inhibitor, was administered to mice bearing Lewis lung carcinoma, T241 fibrosarcoma or B16F10 melanoma. Treatment was stopped when tumours had regressed. Tumours were then allowed to re-grow and endostatin therapy was resumed. After 6, 4 or 2 treatment cycles, respectively, no tumours recurred after discontinuation of therapy. These experiments show that drug resistance does not develop in three tumour types treated with a potent angiogenesis inhibitor. An unexpected finding is that repeated cycles of antiangiogenic therapy are followed by prolonged tumour dormancy without further therapy.

Integrity signals

Registry

Crossref · 10.1038/37126

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

What Is the Evidence That Tumors Are Angiogenesis Dependent?
Folkman, J. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.1.4 · Cited by 4,509
Self-citation
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Self-citation
Thomas, Springfield, Illinois
MAGOUN, H. N. (1965) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-196504000-00011 · Cited by 2,932
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,251
Self-citation
Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
Holmgren, L., O’Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,891
Self-citation
Angiostatin induces and sustains dormancy of human primary tumors in mice
O’Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,170
Self-citation
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents
Kerbel, R. S. (1991) · BioEssays · doi:10.1002/bies.950130106 · Cited by 443
Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas.
Singh, R. K., Gutman, M., BUCANA, C. D., Sanchez, R. R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 437
Tumor angiogenesis and tissue factor
Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0296-167 · Cited by 290
Self-citation
Current results of the screening program at the division of cancer treatment, national cancer institute
GOLDIN, A. S., Venditti, J. M., Macdonald, J. S., Muggia, F. M., Henney, J. E., & DeVita, V. T. (1981) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(81)90027-x · Cited by 209

Flagged first, then by citations

Show all 12 references

Research works printed but not linked: 3

Li, P. L., Schneider, J. A. & Kantor, A. F. in Cancer Medicine 3rd edn Vol. 1(eds Holland, J. F. et al.) 322–339 (Lea & Febiger, Philadelphia, (1993)).
Morrow, C. S. & Cowan, K. H. in Cancer Medicine 3rd edn. Vol. 1(eds Holland, J. F. et al.) 618–630 (Lea & Febiger, Philadelphia, (1993)).
Brem, H., Goto, F., Budson, A., Saunders, L. & Folkman, J. Minimal drug resistance after prolonged anti-angiogenic therapy with AGM-1470. Surg. Forum XLV, 674–677 (1994).

Sorted by citations

Items 201–300 of 1,002

PDGF-D is a potent transforming and angiogenic growth factor
Li, H., Fredriksson, L., Li, X., & Eriksson, U. (2003) · Oncogene · doi:10.1038/sj.onc.1206223 · Cited by 155
On optimal delivery of combination therapy for tumors
d’Onofrio, A., Ledzewicz, U., Maurer, H., & Schättler, H. (2009) · Mathematical Biosciences · doi:10.1016/j.mbs.2009.08.004 · Cited by 154
Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
Takahashi, N., Haba, A., Matsuno, F., & Seon, B. K. (2001) · PubMed · Cited by 150
3,3'-Diindolylmethane inhibits angiogenesis and the growth of transplantable human breast carcinoma in athymic mice
Chang, X. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi018 · Cited by 150
Antiangiogenic therapy—evolving view based on clinical trial results
Jayson, G. C., Hicklin, D. J., & Ellis, L. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.8 · Cited by 149
Establishing a Link between Oncogenes and Tumor Angiogenesis
Kerbel, R. S., Viloria‐Petit, A., Okada, F., & Rak, J. W. (1998) · Molecular Medicine · doi:10.1007/bf03401737 · Cited by 149
The Rationale and Future Potential of Angiogenesis Inhibitors in Neoplasia
Gasparini, G. (1999) · Drugs · doi:10.2165/00003495-199958010-00003 · Cited by 150
Cyclooxygenase, lipoxygenase and tumor angiogenesis
Nie, D.-S., & Honn, K. V. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8468-9 · Cited by 148
Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Karumanchi, S. A., Knebelmann, B., Grüning, W., Dhanabal, M., Walz, G., Stillman, I. E., & Sukhatme, V. P. (1999) · PubMed · Cited by 147
Long-Circulating Polymeric Nanovectors for Tumor-Selective Gene Delivery
Kommareddy, S., Tiwari, S. B., & Amiji, M. M. (2005) · Technology in Cancer Research & Treatment · doi:10.1177/153303460500400605 · Cited by 147
Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy
Sun, X., Kanwar, J. R., Leung, E. Y., Lehnert, K., Wang, D., & Krissansen, G. W. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301388 · Cited by 147
Liposomes Modified with Cyclic RGD Peptide for Tumor Targeting
Dubey, P. K., Mishra, V., Jain, S., Mahor, S., & Vyas, S. P. (2004) · Journal of drug targeting · doi:10.1080/10611860410001728040 · Cited by 144
Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies.
Matsuno, F., Haruta, Y., Kondo, M., Tsai, H., Barcos, M. P., & Seon, B. K. (1999) · PubMed · Cited by 144
Anti-angiogenic therapy: Rationale, challenges and clinical studies
Longo, R., Sarmiento, R., Fanelli, M., Capaccetti, B., Gattuso, D., & Gasparini, G. (2002) · Angiogenesis · doi:10.1023/a:1024532022166 · Cited by 143
Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by Glycyrrhiza glabra
Sheela, M. L., Ramakrishna, M. K., & Salimath, B. P. (2005) · International Immunopharmacology · doi:10.1016/j.intimp.2005.07.002 · Cited by 141
Three Distinct d-Amino Acid Substitutions Confer Potent Antiangiogenic Activity on an Inactive Peptide Derived from a Thrombospondin-1 Type 1 Repeat
Dawson, D. W., Volpert, O. V., Pearce, S. F. A., Schneider, A. J., Silverstein, R. L., Henkin, J., & Bouck, N. (1999) · Molecular Pharmacology · doi:10.1124/mol.55.2.332 · Cited by 141
Combination antitumor therapy with targeted dual-nanomedicines
Dai, W., Wang, X., Song, G., Liu, T., He, B., Zhang, H., Wang, X., & Zhang, Q. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.001 · Cited by 139
Redundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 140
Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-κB: implications for angioprevention and antiangiogenic therapy
Singh, R. P., Dhanalakshmi, S., Agarwal, C., & Agarwal, R. (2004) · Oncogene · doi:10.1038/sj.onc.1208276 · Cited by 139
Liver Regeneration Is an Angiogenesis- Associated Phenomenon
Drixler, T. A., Vogten, M. J., Ritchie, E., van Vroonhoven, T. J. M. V., Gebbink, M. F. B. G., Voest, E. E., & Rinkes, I. H. M. B. (2002) · Annals of Surgery · doi:10.1097/00000658-200212000-00002 · Cited by 139
Minimizing Long-Term Tumor Burden: The Logic for Metronomic Chemotherapeutic Dosing and its Antiangiogenic Basis
Hahnfeldt, P., Folkman, J., & Hlatky, L. (2003) · Journal of Theoretical Biology · doi:10.1006/jtbi.2003.3162 · Cited by 138
Self-citation
A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.
Bhargava, P., Marshall, J. L., Rizvi, N. A., Dahut, W., Yoe, J., Figuera, M., Phipps, K., Ong, V. S., Kato, A., & Hawkins, M. (1999) · PubMed · Cited by 136
Novel Targets for Lung Cancer Therapy: Part I
Dy, G. K., & Adjei, A. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.145 · Cited by 136
Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-Mediated drug resistance
Zeng, X., Morgenstern, R., & Nyström, A. M. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.042 · Cited by 135
Peptide‐Based Multifunctional Nanomaterials for Tumor Imaging and Therapy
Zhang, C., Wu, W. H., Li, R., Qiu, W., Zhuang, Z., Cheng, S., & Zhang, X. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201804492 · Cited by 136
Molecular Mechanisms of Tumor Angiogenesis and Tumor Progression
Cavallaro, U., & Christofori, G. (2000) · Journal of Neuro-Oncology · doi:10.1023/a:1006414621286 · Cited by 139
Aminopeptidase N (APN/CD13) is selectively expressed in vascular endothelial cells and plays multiple roles in angiogenesis
Fukasawa, K., Fujii, H., Saitoh, Y., Koizumi, K., Aozuka, Y., Sekine, K., Yamada, M., Saiki, I., & Nishikawa, K. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.11.051 · Cited by 135
Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells
Kawai, H., Li, H., Chun, P., Avraham, S., & Avraham, H. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205971 · Cited by 135
Angiogenesis and Cancer Control: From Concept to Therapeutic Trial
Brem, S. S. (1999) · Cancer Control · doi:10.1177/107327489900600502 · Cited by 134
Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451
Roberts, W. G., Whalen, P. M., Söderström, E., Moraski, G. C., Lyssikatos, J. P., Wang, H. F., Cooper, B. A., Baker, D. A., Savage, D. M., Dalvie, D., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.957.65.3 · Cited by 134
Heterogeneous Vascular Dependence of Tumor Cell Populations
Yu, J., Rak, J. W., Carmeliet, P., Nagy, A., Kerbel, R. S., & Coomber, B. L. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64083-7 · Cited by 134
Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression
Bullock, M. D., Pickard, K., Nielsen, B. S., Sayan, E., Jenei, V., Mellone, M., Mitter, R., Primrose, J. M., Thomas, G. J., Packham, G., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.213 · Cited by 133
Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
Harada, H., Nakagawa, K., Iwata, S., Saito, M., Kumon, Y., Sakaki, S., Sato, K., & Hamada, K. (1999) · PubMed · Cited by 133
Vascular disrupting agents: a new class of drug in cancer therapy
Gaya, A. M., & Rustin, G. J. S. (2005) · Clinical Oncology · doi:10.1016/j.clon.2004.11.011 · Cited by 133
Vitamin D Binding Protein-Macrophage Activating Factor (DBP-maf) Inhibits Angiogenesis and Tumor Growth in Mice
Kisker, O., Onizuka, S., Becker, C. M., Fannon, M. W., Flynn, E. A., D’Amato, R. J., Zetter, B. R., Folkman, J., Ray, R., Swamy, N., et al. (2003) · Neoplasia · doi:10.1016/s1476-5586(03)80015-5 · Cited by 132
Self-citation
Angiogenesis inhibitor endostatin is a distinct component of elastic fibers in vessel walls
Miosge, N., Sasaki, T., & Timpl, R. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.13.1743 · Cited by 132
Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics
Reiher, F., Volpert, O. V., Jiménez, B., Crawford, S. E., Dinney, C. P., Henkin, J., Haviv, F., Bouck, N., & Campbell, S. C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10247 · Cited by 133
Molecular Imaging of Antiangiogenic Agents
Rehman, S., & Jayson, G. C. (2005) · The Oncologist · doi:10.1634/theoncologist.10-2-92 · Cited by 131
Zinc-dependent dimers observed in crystals of human endostatin
Ding, Y., Javaherian, K., Lo, K.-M., Chopra, R., Boehm, T., Lanciotti, J., Harris, B. A., Li, Y., Shapiro, R., Hohenester, E., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10443 · Cited by 130
Self-citation
Cancer self remission and tumor stability – a stochastic approach
Sarkar, R. R., & Banerjee, S. (2005) · Mathematical Biosciences · doi:10.1016/j.mbs.2005.04.001 · Cited by 128
Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells
Hölig, P., Bach, M., Völkel, T., Nahde, T., Hoffmann, S., Müller, R., & Kontermann, R. E. (2004) · Protein Engineering Design and Selection · doi:10.1093/protein/gzh055 · Cited by 128
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
BEEBE, J. S., Jani, J. P., Knauth, E. A., Goodwin, P., Higdon, C., Rossi, A. M., Emerson, E. O., Finkelstein, M. B., Floyd, E., Harriman, S. P., et al. (2003) · PubMed · Cited by 128
A Peptide Derived from Endostatin Ameliorates Organ Fibrosis
Yamaguchi, Y., Takihara, T., Chambers, R. A., Veraldi, K. L., Larregina, A. T., & Feghali‐Bostwick, C. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003421 · Cited by 127
Peroxisome proliferator-activated receptor γ in malignant diseases
WANG, T., Xu, J., Yu, X., Yang, R., & Han, Z. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.08.011 · Cited by 130
The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase
Lowther, W. T., McMillen, D. A., Orville, A. M., & Matthews, B. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12153 · Cited by 127
Synergy between an antiangiogenic integrin α v antagonist and an antibody–cytokine fusion protein eradicates spontaneous tumor metastases
Lode, H. N., Moehler, T. M., Xiang, R., Jonczyk, A., Gillies, S. D., Cheresh, D. A., & Reisfeld, R. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1591 · Cited by 127
Overview of angiogenesis: Biologic implications for antiangiogenic therapy
Ellis, L. M., Liu, W., Ahmad, S. A., Fan, F., Jung, Y. D., Shaheen, R. M., & Reinmuth, N. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90287-8 · Cited by 125
Matricryptins derived from collagens and proteoglycans
Ricard‐Blum, S. (2010) · Frontiers in bioscience · doi:10.2741/3712 · Cited by 124
Tumor‐vascular interactions and tumor dormancy
Naumov, G. N., Folkman, J., Straume, O., & Akslen, L. A. (2008) · Apmis · doi:10.1111/j.1600-0463.2008.01213.x · Cited by 129
Self-citation
Are tumours angiogenesis‐dependent?
Verheul, H. M. W., Voest, E. E., & Schlingemann, R. O. (2003) · The Journal of Pathology · doi:10.1002/path.1473 · Cited by 125
Optical Imaging of Apoptosis as a Biomarker of Tumor Response to Chemotherapy
Schellenberger, E. A., Bogdanov, A. A., Jr., Petrovsky, A., Ntziachristos, V., Weissleder, R., & Josephson, L. (2003) · Neoplasia · doi:10.1016/s1476-5586(03)80050-7 · Cited by 123
Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 Expression Using Targeted Contrast‐Enhanced High‐Frequency Ultrasonography
Lyshchik, A. P., Fleischer, A. C., Huamani, J., Hallahan, D. E., Briššová, M., & Gore, J. C. (2007) · Journal of Ultrasound in Medicine · doi:10.7863/jum.2007.26.11.1575 · Cited by 123
Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma
Stadler, W. M., Kuzel, T. M., Shapiro, C. M., Sosman, J. A., Clark, J. I., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2541 · Cited by 123
Psychiatric disorders and associated and predictive factors in patients with unresectable nonsmall cell lung carcinoma
Akechi, T., Okamura, H., Nishiwaki, Y., & Uchitomi, Y. (2001) · Cancer · doi:10.1002/1097-0142(20011115)92:10 · Cited by 119
Anticancer drug targets: approaching angiogenesis
Keshet, E., & Ben‐Sasson, S. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8849 · Cited by 123
Immunohistochemical Localization of Vascular Endothelial Growth Factor, Transforming Growth Factor α, and Transforming Growth Factor β1 in Human Corneas with Neovascularization
Cursiefen, C., Rummelt, C., & Küchle, M. (2000) · Cornea · doi:10.1097/00003226-200007000-00025 · Cited by 121
Acoustic droplet vaporization threshold: effects of pulse duration and contrast agent
Lo, A. H., Kripfgans, O. D., Carson, P. L., Rothman, E. D., & Fowlkes, J. B. (2007) · IEEE Transactions on Ultrasonics Ferroelectrics and Frequency Control · doi:10.1109/tuffc.2007.339 · Cited by 121
Novel Cellular Genes Essential for Transformation of Endothelial Cells by Kaposi's Sarcoma–Associated Herpesvirus
Raggo, C. M., Ruhl, R. A., McAllister, S. C., Koon, H. B., Dezube, B. J., Früh, K., & Moses, A. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2822 · Cited by 121
D-limonene rich volatile oil from blood oranges inhibits angiogenesis, metastasis and cell death in human colon cancer cells
Murthy, K. N. C., Jayaprakasha, G. K., & Patil, B. S. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.08.016 · Cited by 120
Is angiogenesis an organizing principle in biology and medicine?
Folkman, J. (2007) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2006.09.048 · Cited by 120
Self-citation
Angiogenesis in hematologic malignancies
Moehler, T. M., Ho, A. D., Goldschmidt, H., & Barlogie, B. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00135-x · Cited by 120
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
Rajkumar, S. V., & Witzig, T. E. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0188 · Cited by 120
Antiangiogenic tumour therapy: will it work?
Augustin, H. G. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01211-5 · Cited by 120
Inhibition of T‐type Ca2+channels by endostatin attenuates human glioblastoma cell proliferation and migration
Zhang, Y., Zhang, J., Jiang, D., Zhang, D., Qian, Z., Liu, C., & Tao, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01852.x · Cited by 119
c-Myc Overexpression Causes Anaplasia in Medulloblastoma
Stearns, D. S., Chaudhry, A., Abel, T. W., Burger, P. C., Dang, C. V., & Eberhart, C. G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1580 · Cited by 119
Angiotensin-I-Converting Enzyme Inhibitors May Be an Alternative Anti-Angiogenic Strategy in the Treatment of Liver Fibrosis and Hepatocellular Carcinoma
Yoshiji, H., Kuriyama, S., & Fukui, H. (2002) · Tumor Biology · doi:10.1159/000069792 · Cited by 119
Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer
Langenkamp, E., & Molema, G. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0642-4 · Cited by 121
Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
Miao, W., Seng, W. L., Duquette, M. A., Lawler, P. R., Laus, C., & Lawler, J. (2001) · PubMed · Cited by 118
Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer
Reynolds, A. R. (2010) · Dose-Response · doi:10.2203/dose-response.09-049.reynolds · Cited by 119
Endostatin: The logic of antiangiogenic therapy
Abdollahi, A., Hlatky, L., & Huber, P. E. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.03.001 · Cited by 119
Signal relays in the VEGF system
Plouët, J. (1999) · Frontiers in bioscience · doi:10.2741/a417 · Cited by 117
Collagen XVIII/Endostatin Structure and Functional Role in Angiogenesis.
Zätterström, U. K., Felbor, U., Fukai, N., & Olsen, B. R. (2000) · Cell Structure and Function · doi:10.1247/csf.25.97 · Cited by 117
Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins With Antitumor Activities
Dings, R. P. M., Chen, X., Hellebrekers, D. M. E. I., van Eijk, L. I., Zhang, Y., Hoye, T. R., Griffioen, A. W., & Mayo, K. H. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj247 · Cited by 116
Frankincense essential oil prepared from hydrodistillation of Boswellia sacra gum resins induces human pancreatic cancer cell death in cultures and in a xenograft murine model
NI, X. Y., Suhail, M. M., Yang, Q., Cao, A., Fung, K., Postier, R. G., Woolley, C., Young, G., Zhang, J., & Lin, H. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-253 · Cited by 116
Anti-neovascular therapy using novel peptides homing to angiogenic vessels
Oku, N., Asai, T., Watanabe, K., Kuromi, K., Nagatsuka, M., Kurohane, K., Kikkawa, H., Ogino, K., Tanaka, M., Ishikawa, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205347 · Cited by 116
Therapeutic Potential of Selective Cyclooxygenase-2 Inhibitors in the Management of Tumor Angiogenesis
Gately, S. T., & Kerbel, R. S. (2003) · KARGER eBooks · doi:10.1159/000071373 · Cited by 116
Endostatin Binds Tropomyosin
MacDonald, N., Shivers, W., Narum, D. L., Plum, S., Wingard, J. N., Fuhrmann, S. R., Liang, H., Holland-Linn, J., Chen, D. H. T., & Sim, B. K. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100743200 · Cited by 117
Applications of Magnetic Resonance in Model Systems: Tumor Biology and Physiology
Gillies, R. J., Bhujwalla, Z. M., Evelhoch, J. L., Garwood, M., Neeman, M., Robinson, S. P., Sotak, C. H., & van der Sanden, B. P. J. (2000) · Neoplasia · doi:10.1038/sj.neo.7900076 · Cited by 116
Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family
Dalal, S., Berry, A. M., Cullinane, C. J., Mangham, D. C., Grimer, R. J., Lewis, I. J., Johnston, C., Laurence, V., & Burchill, S. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1201 · Cited by 115
In vivo prediction of vascular susceptibility to vascular susceptibility endothelial growth factor withdrawal: magnetic resonance imaging of C6 rat glioma in nude mice.
Abramovitch, R., Dafni, H., Smouha, E., Benjamin, L. E., & Neeman, M. (1999) · PubMed · Cited by 115
Health-Related Aspects of Beer: A Review
Sohrabvandi, S., Mortazavian, A. M., & Rezaei, K. (2011) · International Journal of Food Properties · doi:10.1080/10942912.2010.487627 · Cited by 125
Combination Angiostatin and Endostatin Gene Transfer Induces Synergistic Antiangiogenic Activity in Vitro and Antitumor Efficacy in Leukemia and Solid Tumors in Mice
Scappaticci, F. A., Smith, R., Pathak, A., Schloss, D. J., Lum, B. L., Cao, Y., Johnson, F. L., Engleman, E. G., & Nolan, G. P. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0243 · Cited by 114
Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma
de BAZELAIRE, C., Alsop, D. C., George, D. J., Pedrosa, I., Wang, Y., Michaelson, M. D., & Rofsky, N. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0417 · Cited by 113
Antiangiogenic gene therapy of cancer: recent developments
Tandle, A. T., Blazer, D. G., & Libutti, S. K. (2004) · Journal of Translational Medicine · doi:10.1186/1479-5876-2-22 · Cited by 114
Zinc-Binding of Endostatin Is Essential for Its Antiangiogenic Activity
Boehm, T., O’Reilly, M. S., Keough, K. C., Shiloach, J., Shapiro, R., & Folkman, J. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9617 · Cited by 114
Self-citation
Drug Insight: VEGF as a therapeutic target for breast cancer
Schneider, B. P., & Sledge, G. W. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0740 · Cited by 114
Angiogenesis in normal and neoplastic ovaries
Ramakrishnan, S., Subramanian, I. V., Yokoyama, Y., & Geller, M. A. (2005) · Angiogenesis · doi:10.1007/s10456-005-9001-1 · Cited by 112
Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression
Swenson, S. D., Costa, F. K., Minea, R. O., Sherwìn, R. P., Ernst, W. A., Fujii, G., Yang, D., & Markland, F. S. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.499.3.4 · Cited by 112
Beta-elemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis
Chen, W., Lu, Y., Wu, J., Gao, M., Wang, A., & Xu, B. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1378-x · Cited by 112
Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment
Indraccolo, S., Stievano, L., Minuzzo, S. A., Tosello, V., Esposito, G., Piovan, E., Zamarchi, R., Chieco‐Bianchi, L., & Amadori, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506200103 · Cited by 115
Endostatin binds to the catalytic domain of matrix metalloproteinase‐2
Lee, S., Jang, J.-W., Kim, Y.-M., Lee, H. I., Jeon, J. Y., Kwon, Y., & Lee, S. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)02742-4 · Cited by 112
Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma1
de BAZELAIRE, C., Rofsky, N. M., Duhamel, G., Michaelson, M. D., George, D. J., & Alsop, D. C. (2005) · Academic Radiology · doi:10.1016/j.acra.2004.12.012 · Cited by 111
The Role of Vascular Endothelial Growth Factor (VEGF) in Tumor Angiogenesis and Early Clinical Development of VEGFReceptor Kinase Inhibitors
Verheul, H. M. W., & Pinedo, H. M. (2000) · Clinical Breast Cancer · doi:10.3816/cbc.2000.s.015 · Cited by 111
Molecular Regulation of Tumor Angiogenesis and Perfusion via Redox Signaling
Miller, T. W., Isenberg, J. S., & Roberts, D. D. (2009) · Chemical Reviews · doi:10.1021/cr8005125 · Cited by 113
Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches
van Moorselaar, R. J. A., & Voest, E. E. (2002) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00262-9 · Cited by 111
Adeno-associated virus vectors: potential applications for cancer gene therapy
Li, C., Bowles, D. E., Dyke, T. V., & Samulski, R. J. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700876 · Cited by 110
Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations.
Gee, M. S., Saunders, H., Lee, J. C., Sanzo, J. F., Jenkins, W. T., Evans, S. M., Trinchieri, G., Sehgal, C. M., Feldman, M. D., & Lee, W. M. F. (2001) · PubMed · Cited by 110
Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor
Rowe, D. H., Huang, J., Kayton, M. L., Thompson, R., Troxel, A. B., O’Toole, K., Yamashiro, D. J., Stolar, C. J. H., & Kandel, J. J. (2000) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(00)80008-1 · Cited by 109
Tumor angiogenesis as a therapeutic target
Matter, A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)01939-0 · Cited by 108
The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing
Berger, A. C., Feldman, A. L., Gnant, M., Kruger, E. A., Sim, B. K. L., Hewitt, S. M., Figg, W. D., Alexander, H. R., & Libutti, S. K. (2000) · Journal of Surgical Research · doi:10.1006/jsre.2000.5890 · Cited by 108

Authors: Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S.
Affiliations: Harvard University (US)
Dana-Farber/Harvard Cancer Center (US)
Corresponding author: Boehm, Thomas
ORCID: Boehm, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1997-11
Volume: 390
Issue: 6658
Pages: 404-407
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/37126
OpenAlex: W1579297325
Cited by: 1,683
References: 12
Citations by year: 2026: 1 · 2025: 4 · 2024: 11 · 2023: 19 · 2022: 9 · 2021: 19 · 2020: 16 · 2019: 18 · 2018: 15 · 2017: 24 · 2016: 35 · 2015: 25 · 2014: 30 · 2013: 48 · 2012: 47
FWCI: 40.79
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords: anti-angiogenic therapy, acquired drug resistance, endostatin, angiogenesis inhibitors, tumor dormancy, Lewis lung carcinoma, B16F10 melanoma, tumor recurrence, endothelial cells, tumor heterogeneity
MeSH terms: Animals, Antineoplastic Agents, Collagen, Cyclophosphamide, Fibrosarcoma, Melanoma, Experimental, Mice, Inbred C57BL, Neoplasm Recurrence, Local, Neoplasm Transplantation, Neoplasms, Experimental, Neovascularization, Pathologic, Peptide Fragments, Carcinoma, Lewis Lung, Drug Resistance, Neoplasm, Endostatins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks